مباشر

Endpoints NewsAfter 'redesign,' WuXi Biologics sets new timeline for Massachusetts factory completion BioPharma DiveRegenxbio to resubmit gene therapy as FDA backtracks on another drug rejection Endpoints NewsMapLight to discuss autism drug's future with FDA after Phase 2 miss BioPharma DiveSanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends Endpoints NewsLilly allies with BioArctic; Antengene and Insilico sign deals FierceBiotechIn another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy BioWorldBiggest gainers and losers for June 15-19, 2026 BioWorldHoliday notice Endpoints NewsMerck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win FierceBiotechMerck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis PharmaVoicePfizer CFO departs for consumer goods sector FierceBiotechSanofi, Pangaea ink AI partnership deal to detect underdiagnosed genetic disease

FierceBiotech ٢٢ يونيو ٢٠٢٦

Sanofi, Pangaea ink AI partnership deal to detect underdiagnosed genetic disease

French biopharma Sanofi inked a partnership deal with Pangaea Data to use its AI platform that helps detect Alpha-1 Antitrypsin Deficiency (AATD) that will be d...

French biopharma Sanofi inked a partnership deal with Pangaea Data to use its AI platform that helps detect Alpha-1 Antitrypsin Deficiency (AATD) that will be distributed to select healthcare systems and low-income community care clinics.